<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03393481</url>
  </required_header>
  <id_info>
    <org_study_id>CMAA868A2201</org_study_id>
    <secondary_id>2017-002925-39</secondary_id>
    <nct_id>NCT03393481</nct_id>
  </id_info>
  <brief_title>Prevention of Thromboembolic Events in Total Knee Replacement Patients</brief_title>
  <official_title>A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Active-controlled Phase 2 Study to Compare the Efficacy and Safety of s.c. MAA868 Versus s.c. Enoxaparin in Adult Patients Undergoing Unilateral Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to find out whether MAA868, is able to prevent blood clots
      following your medical condition (surgery for knee replacement)
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 3, 2018</start_date>
  <completion_date type="Anticipated">April 17, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 8, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Open-label, blinded endpoint assessment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with confirmed composite endpoint</measure>
    <time_frame>Day 14</time_frame>
    <description>Occurrence of confirmed composite endpoint of asymptomatic deep vein thrombosis (DVT), confirmed symptomatic venous thromboembolic events (VTE), fatal pulmonary embolism (PE) or unexplained death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with composite bleeding</measure>
    <time_frame>Day 1 to Day 50</time_frame>
    <description>Occurrence of confirmed composite endpoint of major bleeding and clinically relevant non-major (CRNM) bleeding events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with composite venous thromboembolic events (VTE)</measure>
    <time_frame>Day 1 to Day 110</time_frame>
    <description>Occurrence of confirmed composite endpoint of asymptomatic deep vein thrombosis (DVT), Confirmed symptomatic venous thromboembolic events (VTE), fatal pulmonary embolism (PE) or unexplained death</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Thrombotic Disorders</condition>
  <arm_group>
    <arm_group_label>MAA868 dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MAA868 dose 1, single administration, subcutaneous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAA868 dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MAA868 dose 2, single administration, subcutaneous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enoxaparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enoxaparin 40mg, once daily (o.d.) for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MAA868</intervention_name>
    <description>MAA868 dose 1 and dose 2, single administration, subcutaneous,</description>
    <arm_group_label>MAA868 dose 1</arm_group_label>
    <arm_group_label>MAA868 dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>Enoxaparin 40 mg, o.d X 10 days</description>
    <arm_group_label>Enoxaparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled to undergo elective unilateral total knee arthroplayts (TKA)

          -  Willing to comply with study requirements including bilateral venography at Day 12 ± 2
             days

          -  Body weight between 50 kg and 130 kg inclusive.

          -  Normal aPTT, PT, INR at screening

        Exclusion Criteria:

        History of arterial or venous thromboembolism; abnormally extended primary or secondary
        bleeding after trauma or intervention, stroke, transient ischemic attack or traumatic or
        non-traumatic intracranial bleed; bleeding disorder; MI or unstable angina pectoris within
        12 months of the screening; Uncontrolled hypertension (SBP/DBP ≥ 150/95 mmHg at the
        screening).

        Medications that increase the risk of bleeding, including antiplatelet (such as aspirin),
        anticoagulant and fibrinolytic agents; eGFR &lt; 60 mL/min/1.73m2; Poorly controlled diabetes
        (HbA1C &gt;10%); Liver dysfunction (ALT/AST &gt;3 xULN or TBL &gt;2 x ULN); BMI ≥ 40 kg/m2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2018</study_first_submitted>
  <study_first_submitted_qc>January 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2018</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>biologic,</keyword>
  <keyword>venous thromboembolism,</keyword>
  <keyword>unilateral knee arthroplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

